EP4698229A1 - Chimères de ciblage de cytotoxicité bispécifique - Google Patents

Chimères de ciblage de cytotoxicité bispécifique

Info

Publication number
EP4698229A1
EP4698229A1 EP24725059.0A EP24725059A EP4698229A1 EP 4698229 A1 EP4698229 A1 EP 4698229A1 EP 24725059 A EP24725059 A EP 24725059A EP 4698229 A1 EP4698229 A1 EP 4698229A1
Authority
EP
European Patent Office
Prior art keywords
formula
group
compound
covalent bond
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24725059.0A
Other languages
German (de)
English (en)
Inventor
Christina Ng Di Marco
Matthew Creed POWELL
Matthew Robert SENDER
Brandon James TURUNEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of EP4698229A1 publication Critical patent/EP4698229A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente divulgation concerne des molécules hétérotrifonctionnelles, appelées chimères ciblant la cytotoxicité (CyTaC) bispécifique ou double ou des molécules de recrutement d'anticorps (ARM) pouvant se lier simultanément à une ou à deux protéines de surface cellulaire cibles ainsi qu'une protéine d'anticorps exogène. La présente divulgation concerne également des agents pouvant se lier à un récepteur sur une surface d'une cellule pathogène et induire la déplétion de la cellule pathogène chez un sujet pour une utilisation dans le traitement du cancer, de maladies inflammatoires, de maladies auto-immunes, d'une infection virale ou d'une infection bactérienne.
EP24725059.0A 2023-04-21 2024-04-19 Chimères de ciblage de cytotoxicité bispécifique Pending EP4698229A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363461181P 2023-04-21 2023-04-21
PCT/EP2024/060829 WO2024218361A1 (fr) 2023-04-21 2024-04-19 Chimères de ciblage de cytotoxicité bispécifique

Publications (1)

Publication Number Publication Date
EP4698229A1 true EP4698229A1 (fr) 2026-02-25

Family

ID=91070116

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24725059.0A Pending EP4698229A1 (fr) 2023-04-21 2024-04-19 Chimères de ciblage de cytotoxicité bispécifique

Country Status (3)

Country Link
EP (1) EP4698229A1 (fr)
JP (1) JP2026514797A (fr)
WO (1) WO2024218361A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
CA2388245C (fr) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1423510A4 (fr) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
KR101318611B1 (ko) 2005-07-22 2013-11-13 교와 핫꼬 기린 가부시키가이샤 유전자 재조합 항체 조성물
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US20250136722A1 (en) * 2021-08-13 2025-05-01 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras

Also Published As

Publication number Publication date
WO2024218361A1 (fr) 2024-10-24
JP2026514797A (ja) 2026-05-13

Similar Documents

Publication Publication Date Title
WO2023017484A1 (fr) Chimères ciblant la cytotoxicité
AU2024336691A1 (en) Macrocyclic compound and antibody-drug conjugate thereof
ES3058142T3 (en) Cytotoxicity targeting chimeras for ccr2-expressing cells
KR102672512B1 (ko) 항바이러스 피리도피라진디온 화합물
KR20260034686A (ko) 치환된 헤테로환 및 이의 용도
US20250057958A1 (en) Cytotoxicity targeting chimeras for ccr2-expressing cells
US20250154288A1 (en) Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cells
US20250064947A1 (en) Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
KR20250152075A (ko) 거대환식 알파4베타7 인테그린 억제제
US20250057827A1 (en) Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
US20250049932A1 (en) Cytotoxicity targeting chimeras for folate receptor-expressing cells
US20250051479A1 (en) Cytotoxicity targeting chimeras for cxcr3-expressing cells
WO2023161877A1 (fr) Chimères ciblant la cytotoxicité pour des cellules exprimant l'intégrine avb6
WO2025085489A1 (fr) Composés de dégradation de gspt1, anticorps anti-cd33 et conjugués anticorps-médicament, et leurs utilisations
WO2024218361A1 (fr) Chimères de ciblage de cytotoxicité bispécifique
HK40108044A (en) Cytotoxicity targeting chimeras for ccr2-expressing cells
HK40108044B (en) Cytotoxicity targeting chimeras for ccr2-expressing cells

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251021

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)